1[1]Mantzaris G J, Archavlis E, Christoforidis P, et al. A prospective randomized controlled trial of oral ciprofloxacin in acute ulcerative colitis[J]. Am J Gastroenterol, 1997, 92(3): 454.
2[2]Dickinson R J, O'connor H J, Pinder I, et al. Double blind controlled trial of oral vancomycin as adjunctive treatment in acute exacerbations of idiopathic colitis[J]. Gut, 1985, 26(12): 1380.
3[3]Chapman R W, Selby W S, Jewell D P. Controlled trial of intravenous metronidazole as an adjunct to corticosteroids in severe ulcerative colitis[J]. Gut, 1986, 27(10): 1210.
4[4]Burke D A, Axon A T R, Clayden S A, et al. The efficacy of tobramycin in the treatment of ulcerative colitis[J]. Aliment Pharmacol Therap, 1990, 4(2): 123.
5[5]Mantzaris G J, Hatzis A, Kontogiannis Ph, et al. Intravenous tobramycin and metronidazole as an adjunct to corticosteroids in acute, severe ulcerative colitis[J]. Am J Gastroenterol, 1994, 89(1): 43.
6[6]Turunen U M, Farkkila M A, Hakala K, et al. Long-term treatment of ulcerative colitis with ciprofloxacin: a prospective, double-blind, placebo-controlled study[J]. Gastroenterology, 1998, 115(5):1072.
7[7]Gionchetti P, Rizzello F, Ferrieri A, et al. Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid-treatment: a double-blind, placebo-controlled trial[J]. Dig Dis Sci, 1999,44(6): 1220.
8[8]Campieri M,Bertinelli E,Gionchetti P, et al. Requirements for the use of intestinal action antibactics in the treatment of ulcerative colitis[J]. Ital J Gastroenterol, 1992, 24(9 Suppl 2): 2.
9[9]Gionchetti P, Rizzello F, Venturi A, et al. Review--antibactic treatment in inflammatory bowel disease: rifaximin, a new possible approach[J]. Eur Rev Med Pharmacol Sci, 1999, 3(1): 27.
